South Korea · Delayed Price · Currency is KRW Theragen Etex Statistics
Total Valuation
Theragen Etex has a market cap or net worth of KRW 114.82 billion. The enterprise value is 138.61 billion.
| Market Cap | 114.82B |
| Enterprise Value | 138.61B |
Important Dates
The last earnings date was Thursday, April 2, 2026.
| Earnings Date | Apr 2, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Theragen Etex has 36.68 million shares outstanding. The number of shares has increased by 14.25% in one year.
| Current Share Class | 36.68M |
| Shares Outstanding | 36.68M |
| Shares Change (YoY) | +14.25% |
| Shares Change (QoQ) | +12.45% |
| Owned by Insiders (%) | 27.45% |
| Owned by Institutions (%) | 0.85% |
| Float | 24.11M |
Valuation Ratios
The trailing PE ratio is 10.79.
| PE Ratio | 10.79 |
| Forward PE | n/a |
| PS Ratio | 0.42 |
| PB Ratio | 0.72 |
| P/TBV Ratio | 0.86 |
| P/FCF Ratio | 13.68 |
| P/OCF Ratio | 10.46 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 8.31, with an EV/FCF ratio of 16.51.
| EV / Earnings | 13.08 |
| EV / Sales | 0.51 |
| EV / EBITDA | 8.31 |
| EV / EBIT | 13.57 |
| EV / FCF | 16.51 |
Financial Position
The company has a current ratio of 1.58, with a Debt / Equity ratio of 0.26.
| Current Ratio | 1.58 |
| Quick Ratio | 1.18 |
| Debt / Equity | 0.26 |
| Debt / EBITDA | 2.50 |
| Debt / FCF | 4.96 |
| Interest Coverage | 4.38 |
Financial Efficiency
Return on equity (ROE) is 8.11% and return on invested capital (ROIC) is 4.36%.
| Return on Equity (ROE) | 8.11% |
| Return on Assets (ROA) | 2.58% |
| Return on Invested Capital (ROIC) | 4.36% |
| Return on Capital Employed (ROCE) | 6.06% |
| Weighted Average Cost of Capital (WACC) | 4.68% |
| Revenue Per Employee | 1.21B |
| Profits Per Employee | 47.32M |
| Employee Count | 224 |
| Asset Turnover | 1.10 |
| Inventory Turnover | 3.86 |
Taxes
In the past 12 months, Theragen Etex has paid 5.79 billion in taxes.
| Income Tax | 5.79B |
| Effective Tax Rate | 33.03% |
Stock Price Statistics
The stock price has increased by +5.92% in the last 52 weeks. The beta is 0.14, so Theragen Etex's price volatility has been lower than the market average.
| Beta (5Y) | 0.14 |
| 52-Week Price Change | +5.92% |
| 50-Day Moving Average | 2,783.10 |
| 200-Day Moving Average | 2,860.08 |
| Relative Strength Index (RSI) | 71.15 |
| Average Volume (20 Days) | 115,022 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Theragen Etex had revenue of KRW 271.59 billion and earned 10.60 billion in profits. Earnings per share was 290.00.
| Revenue | 271.59B |
| Gross Profit | 141.01B |
| Operating Income | 10.21B |
| Pretax Income | 17.54B |
| Net Income | 10.60B |
| EBITDA | 16.69B |
| EBIT | 10.21B |
| Earnings Per Share (EPS) | 290.00 |
Balance Sheet
The company has 38.02 billion in cash and 41.65 billion in debt, with a net cash position of -3.62 billion or -98.69 per share.
| Cash & Cash Equivalents | 38.02B |
| Total Debt | 41.65B |
| Net Cash | -3.62B |
| Net Cash Per Share | -98.69 |
| Equity (Book Value) | 159.17B |
| Book Value Per Share | 3,766.70 |
| Working Capital | 51.51B |
Cash Flow
In the last 12 months, operating cash flow was 10.97 billion and capital expenditures -2.58 billion, giving a free cash flow of 8.40 billion.
| Operating Cash Flow | 10.97B |
| Capital Expenditures | -2.58B |
| Depreciation & Amortization | 6.48B |
| Net Borrowing | -8.29B |
| Free Cash Flow | 8.40B |
| FCF Per Share | 228.87 |
Margins
Gross margin is 51.92%, with operating and profit margins of 3.76% and 3.90%.
| Gross Margin | 51.92% |
| Operating Margin | 3.76% |
| Pretax Margin | 6.46% |
| Profit Margin | 3.90% |
| EBITDA Margin | 6.14% |
| EBIT Margin | 3.76% |
| FCF Margin | 3.09% |
Dividends & Yields
Theragen Etex does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 0.94% |
| Buyback Yield | -14.25% |
| Shareholder Yield | -14.25% |
| Earnings Yield | 9.23% |
| FCF Yield | 7.31% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Theragen Etex has an Altman Z-Score of 2.06 and a Piotroski F-Score of 8. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.06 |
| Piotroski F-Score | 8 |